← Research library

Ventvil Phase II placebo-controlled liver disease trial registration (VNT-08-2018)

Planned study · 2019

Registered population or design
130 planned participants with alcohol-associated liver disease. Final enrollment and arm sizes are unavailable.
Results availability
The Phase II registry lists 130 planned participants in a randomized placebo-controlled comparison of injected Ventvil in alcohol-associated liver disease. Clinical results remain unavailable.

Study data at a glance

Participants or experimental model
130 planned participants with alcohol-associated liver disease. Final enrollment and arm sizes are unavailable.
Dose, route and schedule
Multicenter, single-blind, randomized parallel comparison of intramuscular Ventvil dose schedules with placebo. The listing gives 5 mg as vial strength and does not specify the injection frequency or arm schedules.
Registered study design
The Phase II registry lists 130 planned participants in a randomized placebo-controlled comparison of injected Ventvil in alcohol-associated liver disease. Clinical results remain unavailable.

Protocol source ↗ · Registry entry for VNT-08-2018

Sponsor, trial investigators and public sources ↗

Study limitations and source details

Study limitations

  • The registry mirror lists the trial as completed in 2020. The registry mirror enumerates 11 organizations. ClinLine gives 12 in its header and lists 11 by name. Both give 130 planned participants. Enrollment, arm doses and schedules, clinical outcomes and adverse-event counts remain unavailable.
  • 5 mg is the strength of the injectable vial. The registry record does not establish what each arm received.

Source details

Clinical trial registration

Authorization No. 120, sponsor and contract research organization listings, investigator profiles and accessible Russian conference programs. Public sources provide registration details.

Sources checked

Added to the library

Citation

Trial protocol / registrationFull text available

MedInvest (sponsor). Ventvil Phase II placebo-controlled liver disease trial registration (VNT-08-2018) Russian clinical-trial register entry via ClinLine. Authorization No. 120, 13 March 2019

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards